The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Open accessAbstract
Abeta1-42 is a self-associating peptide whose neurotoxic derivatives are thought to play a role in Alzheimer's pathogenesis. Neurotoxicity of amyloid beta protein (Abeta) has been attributed to its fibrillar forms, but experiments presented here characterize neurotoxins that assemble when fibril formation is inhibited. These neurotoxins comprise small diffusible Abeta oligomers (referred to as ADDLs, for Abeta-derived diffusible ligands), which were found to kill mature neurons in organotypic central nervous system cultures at nanomolar concentrations. At cell surfaces, ADDLs bound to trypsin-sensitive sites and surface-derived tryptic peptides blocked binding and afforded neuroprotection. Germ-line knockout of Fyn, a protein tyrosine kinase linked to apoptosis and elevated in Alzheimer's disease, also was neuroprotective. Remarkably, neurological dysfunction evoked by ADDLs occurred well in advance of cellular degeneration. Without lag, and despite retention of evoked action potentials, ADDLs inhibited hippocampal long-term potentiation, indicating an immediate impact on signal transduction. We hypothesize that impaired synaptic plasticity and associated memory dysfunction during early stage Alzheimer's disease and severe cellular degeneration and dementia during end stage could be caused by the biphasic impact of Abeta-derived diffusible ligands acting upon particular neural signal transduction pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, recent in vivo studies have shown that soluble Aβ oligomers are more neurotoxic than amyloid plaques and most likely responsible for synaptic dysfunction and memory loss in AD.7–11”
From The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity (2013) · cites this paper as [10]
In the citing paper
“However, recent in vivo studies have shown that the soluble Aβ oligomers are possibly more neurotoxic than amyloid plaques,14–17 and are likely responsible for synaptic dysfunction and memory loss in AD patients and AD animal models.18–21”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [14]
In the citing paper
“recent studies have shown that the soluble Aβ oligomers are more neurotoxic both in vitro and in vivo.5−8”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [7]
In the citing paper
“For the preformed Aβ42 fibrils, no significant cell toxicity was observed in either the absence or presence of Cu2+ (Figure 9, lanes 1 and 2), supporting the previously reported diminished toxicity of Aβ42 fibrils.5,7,54−56”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [7]
In the citing paper
“This function may be critical in controlling Aβ deposition as well as levels of potentially neurotoxic Aβ oligomers (Lambert et al., 1998).”
From CX3CR1 in Microglia Regulates Brain Amyloid Deposition through Selective Protofibrillar Amyloid-β Phagocytosis (2010) · cites this paper as Lambert et al., 1998
In the citing paper
“While Aβ disrupts synaptic transmission 32,34,35 and induces synapse loss 17”
From NAD+ hydrolase Sarm1 is a key driver of synapse degeneration and memory loss in Alzheimer’s disease (2025) · cites this paper as [34]
In the citing paper
“In vitro, apoE and apoJ form stable complexes with A (11, 16 -20), alter the aggregation of various A peptides (21)(22)(23), and affect A neurotoxicity (24 -27).”
From Apolipoprotein E Receptors Mediate the Effects of β-Amyloid on Astrocyte Cultures (2000) · cites this paper as [27]
In the citing paper
“A 1-42 aged according to this protocol is a mixture of fibrils and soluble globular aggregates, and is active to astrocytes (37,38) and toxic to neurons (26,27).”
From Apolipoprotein E Receptors Mediate the Effects of β-Amyloid on Astrocyte Cultures (2000) · cites this paper as [27]
In the citing paper
“ApoJ has been shown to potentiate the formation of a neurotoxic species of A (26,27).”
From Apolipoprotein E Receptors Mediate the Effects of β-Amyloid on Astrocyte Cultures (2000) · cites this paper as [27]
In the citing paper
“ApoE, apoJ, and most recently ␣ 2 -macroglobulin have been shown to form a complex with A that may facilitate clearance of the peptide (25-27, 50, 51).”
From Apolipoprotein E Receptors Mediate the Effects of β-Amyloid on Astrocyte Cultures (2000) · cites this paper as [27]
In the citing paper
“Evidence suggests that increased uptake of these neurotoxic Aβ42 peptides results in accumulation and aggregation within neurons eventually leading the formation of plaques and neuronal death [40, 41].”
From The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsible for the Cellular Uptake of Aβ42 and Its Protein Aggregates (2020) · cites this paper as [41]
In the citing paper
“Most importantly, these amyloid-free Aβ oligomers were potent CNS neurotoxins.”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lambert et al., 1998
In the citing paper
“With chronic exposure, neurons ultimately were killed. Death was selective for subpopulations of vulnerable neurons and was prevented by knockout of Fyn, a protein tyrosine kinase linked to NMDA receptor signaling.”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lambert et al., 1998
In the citing paper
“Investigation into the action of clusterin by Lambert, Klein and colleagues established that, concomitant with inhibition of amyloid formation, clusterin promotes accumulation of soluble Aβ oligomers (Lambert et al., 1998).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lambert et al., 1998
In the citing paper
“oligomers were found to inhibit functional synaptic plasticity (Lambert et al., 1998). Long-term potentiation (LTP) was inhibited within minutes. This rapid loss of LTP, measured in rat brain slices and in situ in mice, occurred without impact on baseline excitability, indicating impairment of signaling rather than degeneration.”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lambert et al., 1998
In the citing paper
“In hippocampal slices, synthetic oligomers cause rapid LTP inhibition (Barghorn et al., 2005; Fa et al., 2010; Jurgensen et al., 2011; Lambert et al., 1998; Nimmrich et al., 2008; Rammes et al., 2011; Wang et al., 2002).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lambert et al., 1998
In the citing paper
“early studies showed that binding is lost upon controlled trypsin treatment of neurons (Lambert et al., 1998).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lambert et al., 1998
In the citing paper
“In vitro and in vivo studies have now indicated that soluble Aβ oligomers impair synaptic plasticity, inhibiting hippocampal long-term potentiation (LTP), the electrophysiological correlate of learning and memory (3 –6).”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [3]
Citations
Cites
Mass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels
Shevchenko, A., Wilm, M. S., Vorm, O., & Mann, M. (1996) · Analytical Chemistry · doi:10.1021/ac950914h · Cited by 8,996
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
A simple method for organotypic cultures of nervous tissue
Stoppini, L., Buchs, P., & Muller, D. (1991) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(91)90128-m · Cited by 3,096
Integrins and Signal Transduction Pathways: the Road Taken
Clark, E. A., & Brugge, J. S. (1995) · Science · doi:10.1126/science.7716514 · Cited by 2,911
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975
Flagged first, then by citations
Research works printed but not linked: 2
- B Leveugle, A Scanameo, W Ding, H Fillit NeuroReport 5, 1389–1392 (1994).
- 10.1146/annurev.bi.63.070194.003125 · DOI
Cited by
Sorted by citations
Items 401–500 of 1,060
Zhang, J., Li, X., & Li, J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00381 · Cited by 225
Kiyota, T., Okuyama, S., Swan, R. J., Jacobsen, M. T., Gendelman, H. E., & Ikezu, T. (2010) · The FASEB Journal · doi:10.1096/fj.10-155317 · Cited by 212
β-Amyloid Regulation of Presynaptic Nicotinic Receptors in Rat Hippocampus and Neocortex
Dougherty, J. J., Wu, J., & Nichols, R. A. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-17-06740.2003 · Cited by 213
Behavioral assays with mouse models of Alzheimer's disease: Practical considerations and guidelines
Puzzo, D., Lee, L. S., Palmeri, A., Calabrese, G., & Arancio, O. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.011 · Cited by 226
Clarke, J. R., Lyra e Silva, N. M., Figueiredo, C. P., Frozza, R. L., Ledo, J. H., Beckman, D., Katashima, C. K., Razolli, D., Carvalho, B. M., Frazão, R., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404183 · Cited by 214
Self-citationHong, S., Ostaszewski, B. L., Yang, T., O’Malley, T. T., Jin, M., Yanagisawa, K., Li, S., Bartels, T., & Selkoe, D. J. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.027 · Cited by 213
Selection of DNA Aptamers That Recognize α-Synuclein Oligomers Using a Competitive Screening Method
Tsukakoshi, K., Abe, K., Sode, K., & Ikebukuro, K. (2012) · Analytical Chemistry · doi:10.1021/ac300330g · Cited by 211
Methylene Blue Inhibits Amyloid Aβ Oligomerization by Promoting Fibrillization
Necula, M., Breydo, L., Milton, S., Kayed, R., van der Veer, W. E., Tone, P., & Glabe, C. G. (2007) · Biochemistry · doi:10.1021/bi700411k · Cited by 213
Lipid-based nanoparticles with high binding affinity for amyloid-β1–42 peptide
Gobbi, M., Re, F., Canovi, M., Beeg, M., Gregori, M., Sesana, S., Sonnino, S., Brogioli, D., Musicanti, C., Gasco, P., et al. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.04.044 · Cited by 192
Structural studies of soluble oligomers of the alzheimer β-amyloid peptide
Huang, T. H. J., Dun-Sheng, Y., Plaskos, N. P., Go, S., Yip, C. M., Fraser, P. E., & Chakrabartty, A. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3559 · Cited by 211
Alzheimer disease and Down syndrome: factors in pathogenesis
Lott, I. T., & Head, E. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.08.005 · Cited by 212
Dineley, K. T., Xia, X., Bui, D., Sweatt, J. D., & Zheng, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200164200 · Cited by 212
Fullerene inhibits β-amyloid peptide aggregation
Kim, J. E., & Lee, M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00393-0 · Cited by 212
Reversal of mutant myocilin non-secretion and cell killing: implications for glaucoma
Liu, Y., & Vollrath, D. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh128 · Cited by 214
Hung, L. W., Ciccotosto, G. D., Giannakis, E., Tew, D. J., Perez, K., Masters, C. L., Cappai, R., Wade, J. D., & Barnham, K. J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3916-08.2008 · Cited by 210
Selective neuronal degeneration induced by soluble oligomeric amyloid beta‐protein
Kim, H., Chae, S., Lee, D., Chromy, B. A., Lee, S. C., Park, Y., Klein, W. L., Krafft, G. A., & Hong, S. (2002) · The FASEB Journal · doi:10.1096/fj.01-0987fje · Cited by 219
Self-citationProteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain
Butterfield, D. A. (2004) · Brain Research · doi:10.1016/j.brainres.2003.12.012 · Cited by 210
Systemic Catabolism of Alzheimer's Aβ40 and Aβ42
Ghiso, J., Shayo, M., Calero, M., Ng, D., Tomidokoro, Y., Gandy, S., Rostagno, A., & Frangione, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407668200 · Cited by 209
Moreno‐González, I., Edwards, G. A., Salvadores, N., Shahnawaz, M., Díaz‐Espinoza, R., & Soto, C. A. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.230 · Cited by 215
Sarell, C. J., Syme, C. D., Rigby, S. E. J., & Viles, J. H. (2009) · Biochemistry · doi:10.1021/bi900254n · Cited by 209
Heart Failure and Protein Quality Control
Wang, X., & Robbins, J. M. (2006) · Circulation Research · doi:10.1161/01.res.0000252342.61447.a2 · Cited by 212
Ion Channel Formation by Amyloid-β42 Oligomers but Not Amyloid-β40 in Cellular Membranes
Bode, D. C., Baker, M. D., & Viles, J. H. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.762526 · Cited by 210
Replication of CLU, CR1, and PICALM Associations With Alzheimer Disease
Carrasquillo, M. M., Belbin, O., Hunter, T. A., Ma, L., Bisceglio, G. D., Zou, F., Crook, J. E., Pankratz, V. S., Dickson, D. W., Graff-Radford, N. R., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.147 · Cited by 208
Metals ions and neurodegeneration
Molina‐Holgado, F., Hider, R. C., Gaeta, A., Williams, R., & Francis, P. T. (2007) · BioMetals · doi:10.1007/s10534-006-9033-z · Cited by 206
Kirouac, L., Rajic, A. J., Cribbs, D. H., & Padmanabhan, J. (2017) · eneuro · doi:10.1523/eneuro.0149-16.2017 · Cited by 207
Tong, L., Thornton, P. L., Balazs, R., & Cotman, C. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010450200 · Cited by 206
Walsh, D. M., Klyubin, I., Shankar, G. M., Townsend, M., Fadeeva, J. V., Betts, V., Podlisny, M. B., Cleary, J. P., Ashe, K. H., Rowan, M. J., et al. (2005) · Biochemical Society Transactions · doi:10.1042/bst20051087 · Cited by 222
The synaptic Aβ hypothesis of Alzheimer disease
Tanzi, R. E. (2005) · Nature Neuroscience · doi:10.1038/nn0805-977 · Cited by 206
Cellular Proteostasis in Neurodegeneration
Kurtishi, A., Rosen, B., Patil, K. S., Alves, G. W., & Møller, S. G. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1334-z · Cited by 210
Hladky, S. B., & Barrand, M. A. (2018) · Fluids and Barriers of the CNS · doi:10.1186/s12987-018-0113-6 · Cited by 206
Clusterin contributes to caspase-3–independent brain injury following neonatal hypoxia-ischemia
Han, B. H., Demattos, R. B., Dugan, L. L., Kim‐Han, J. S., Brendza, R. P., Fryer, J. D., Kierson, M., Cirrito, J. R., Quick, K. L., Harmony, J. A. K., et al. (2001) · Nature Medicine · doi:10.1038/85487 · Cited by 208
The evolution of Alzheimer disease, the reproductive schedule, and apoE isoforms☆
Finch, C. E., & Sapolsky, R. M. (1999) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00053-6 · Cited by 208
Self-citationLipoproteins in the Central Nervous System
LADU, M. J., REARDON, C., VAN ELDIK, L., FAGAN, A. M., BU, G., HOLTZMAN, D., & GETZ, G. S. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06365.x · Cited by 167
Tchantchou, F., Xu, Y., Wu, Y., Christen, Y., & Luo, Y. (2007) · The FASEB Journal · doi:10.1096/fj.06-7649com · Cited by 203
The Insulin/Akt Signaling Pathway Is Targeted by Intracellular β-Amyloid
Lee, H.-K., Kumar, P., Fu, Q., Rosen, K. M., & Querfurth, H. W. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-07-0777 · Cited by 185
Calcium/calmodulin-dependent kinase II and Alzheimer’s disease
Ghosh, A., & Giese, K. P. (2015) · Molecular Brain · doi:10.1186/s13041-015-0166-2 · Cited by 205
An ESIPT Probe for the Ratiometric Imaging of Peroxynitrite Facilitated by Binding to Aβ-Aggregates
Sedgwick, A. C., Dou, W., Jiao, J., Wu, L., Williams, G. T., Jenkins, A. T. A., Bull, S. D., Sessler, J. L., He, X., & James, T. D. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b08457 · Cited by 205
Powers, E. T., & Powers, D. L. (2007) · Biophysical Journal · doi:10.1529/biophysj.107.117168 · Cited by 207
Vanillic acid attenuates Aβ1-42-induced oxidative stress and cognitive impairment in mice
Amin, F. U., Shah, S. A., & Kim, M. O. (2017) · Scientific Reports · doi:10.1038/srep40753 · Cited by 205
Disease-specific tau filaments assemble via polymorphic intermediates
Lövestam, S., Li, D., Wagstaff, J. L., Kotecha, A., Kimanius, D., McLaughlin, S. H., Murzin, A. G., Freund, S. M. V., Goedert, M., & Scheres, S. H. W. (2023) · Nature · doi:10.1038/s41586-023-06788-w · Cited by 207
Luibl, V. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25843 · Cited by 203
Behl, C., & Moosmann, B. (2002) · Biological Chemistry · doi:10.1515/bc.2002.053 · Cited by 203
Calcium dysregulation in Alzheimer's disease
Bojarski, Ł., Herms, J. W., & Kuźnicki, J. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.10.002 · Cited by 207
Cholinergic Neuronal and Axonal Abnormalities Are Present Early in Aging and in Alzheimer Disease
Geula, C., Nagykery, N. G., Nicholas, A., & Wu, C. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31816a1df3 · Cited by 204
Natural product-based amyloid inhibitors
Velander, P., Wu, L., Henderson, F. E., Zhang, S., Bevan, D. R., & Xu, B. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.04.004 · Cited by 207
Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide
Sharma, A. K., Pavlova, S. T., Kim, J., Finkelstein, D., Hawco, N. J., Rath, N. P., Kim, J., & Mirica, L. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja210588m · Cited by 202
Synaptic plasticity in animal models of early Alzheimer's disease
Rowan, M. J., Klyubin, I. V., Cullen, W. K., & Anwyl, R. (2003) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2002.1240 · Cited by 206
Molecular links between Alzheimer’s disease and diabetes mellitus
Yang, Y., & Song, W. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.07.009 · Cited by 211
Origlia, N., Righi, M., Capsoni, S., Cattaneo, A., Fang, F., Stern, D. M., Chen, J. X., Schmidt, A. M., Arancio, O., Yan, S. D., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0204-08.2008 · Cited by 206
Fu, A. K. Y., Hung, K.-W., Huang, H., Gu, S., Shen, Y., Cheng, E. Y. L., Ip, F. C. F., Huang, X., Fu, W.-Y., & Ip, N. Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405803111 · Cited by 201
Mechanisms of islet amyloidosis toxicity in type 2 diabetes
Abedini, A., & Schmidt, A. M. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.01.017 · Cited by 206
Emerging roles of pathogens in Alzheimer disease
Miklossy, J. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002006 · Cited by 206
Metabotropic NMDA receptor function is required for β-amyloid–induced synaptic depression
Kessels, H. W. H. G., Nabavi, S., & Malinow, R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219605110 · Cited by 206
Chen, W.-T., Liao, Y., Yu, H.-M., Cheng, I. H.-J., & Chen, Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.177246 · Cited by 199
Fyn kinase inhibition as a novel therapy for Alzheimer’s disease
Nygaard, H. B., van Dyck, C. H., & Strittmatter, S. M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt238 · Cited by 206
Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?
Öhrfelt, A., Grognet, P., Andreasen, N., Wallin, A., Vanmechelen, E., Blennow, K., & Zetterberg, H. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.11.015 · Cited by 201
β-Amyloid impairs axonal BDNF retrograde trafficking
Poon, W. W., Blurton-Jones, M. M., Tu, C. H., Feinberg, L. M., Chabrier, M. A., Harris, J. W., Jeon, N. L., & Cotman, C. W. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.05.012 · Cited by 203
Oligomeric amyloid-β peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism
Berman, D. E., Dall'Armi, C., Voronov, S. V., McIntire, L. B. J., Zhang, H., Moore, A. Z., Staniszewski, A., Arancio, O., Kim, T.-W., & Di Paolo, G. (2008) · Nature Neuroscience · doi:10.1038/nn.2100 · Cited by 199
Russo, C., Violani, E., Salis, S., Venezia, V., Dolcini, V., Damonte, G., Benatti, U., D’Arrigo, C., Patrone, E., Carlo, P., et al. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01107.x · Cited by 204
Metabolite-initiated protein misfolding may trigger Alzheimer's disease
Zhang, Q., Powers, E. T., Nieva, J. J., Huff, M. E., Dendle, M. A., Bieschke, J., Glabe, C. G., Eschenmoser, A., Wentworth, P., Lerner, R. A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400924101 · Cited by 197
Amyloid β, Glutamate, Excitotoxicity in Alzheimer's Disease: Are We on the Right Track?
Esposito, Z., Belli, L., Toniolo, S., Sancesario, G., Bianconi, C., & Martorana, A. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12095 · Cited by 215
Kokkoni, N., Stott, K., Amijee, H., Mason, J. M., & Doig, A. J. (2006) · Biochemistry · doi:10.1021/bi060837s · Cited by 204
Correia, S. C., Santos, R. X., Carvalho, C., Cardoso, S., Candeias, E., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2012) · Brain Research · doi:10.1016/j.brainres.2011.12.063 · Cited by 202
Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Aβ oligomerization
Felice, F. G. D., Vieira, M. N. N., Saraiva, L. M., Figueroa‐Villar, J. D., Garcia-Abreu, J., Liu, R., Chang, L., Klein, W. L., & Ferreira, S. T. (2004) · The FASEB Journal · doi:10.1096/fj.04-1764com · Cited by 196
Self-citationIbuprofen reduces Aβ, hyperphosphorylated tau and memory deficits in Alzheimer mice
McKee, A. C., Carreras, I., Hossain, L., Ryu, H., Klein, W. L., Oddo, S., LaFerla, F. M., Jenkins, B. G., Kowall, N. W., & Dedeoglu, A. (2008) · Brain Research · doi:10.1016/j.brainres.2008.01.095 · Cited by 201
Self-citationCSF Biomarkers for Alzheimer's Disease Diagnosis
Arunagiri, A., Singh, P. K., Jacob, R. S., & Maji, S. K. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/606802 · Cited by 215
Wang, Q., Rowan, M. J., & Anwyl, R. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.0233-04.2004 · Cited by 197
Molecular Dynamics Simulation of Amyloid β Dimer Formation
Urbanc, B., Cruz, L., Ding, F., Sammond, D. W., Khare, S. D., Buldyrev, S. V., Stanley, E., & Dokholyan, N. V. (2004) · Biophysical Journal · doi:10.1529/biophysj.104.040980 · Cited by 194
Hu, N., Nicoll, A. J., Zhang, D., Mably, A. J., O’Malley, T. T., Purro, S. A., Terry, C., Collinge, J., Walsh, D. M., & Rowan, M. J. (2014) · Nature Communications · doi:10.1038/ncomms4374 · Cited by 192
Alzheimer’s Disease, Oligomers, and Inflammation
Forloni, G., & Balducci, C. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170819 · Cited by 205
β-Amyloid Is Different in Normal Aging and in Alzheimer Disease
Piccini, A., Russo, C., Gliozzi, A., Relini, A., Vitali, A., Borghi, R., Giliberto, L., Armirotti, A., D’Arrigo, C., Bachi, A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501694200 · Cited by 192
Coarse-grained models for protein aggregation
Wu, C. F., & Shea, J. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.02.002 · Cited by 191
The Therapeutic Potential of Rosemary (Rosmarinus officinalis) Diterpenes for Alzheimer’s Disease
Habtemariam, S. (2016) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2016/2680409 · Cited by 195
The duality of amyloid-β: its role in normal and Alzheimer’s disease states
Azargoonjahromi, A. (2024) · Molecular Brain · doi:10.1186/s13041-024-01118-1 · Cited by 214
Gralle, M., & Ferreira, S. T. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.02.001 · Cited by 202
Nilsson, K. P. R., Åslund, A., Berg, I., Nyström, S., Konradsson, P., Herland, A., Inganäs, O., Stabo-Eeg, F., Lindgren, M., Westermark, G. T., et al. (2007) · ACS Chemical Biology · doi:10.1021/cb700116u · Cited by 191
Animal models of Alzheimer's disease and evaluation of anti-dementia drugs
Yamada, K., & Nabeshima, T. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00081-4 · Cited by 192
Goure, W. F., Krafft, G. A., Jerecic, J., & Hefti, F. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt272 · Cited by 190
Self-citationBellotti, V., Mangione, P., & Merlini, G. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4248 · Cited by 198
Lindquist, S., & Kelly, J. W. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004507 · Cited by 192
Jiménez, S., Torres, M., Vizuete, M., Sanchez-Varo, R. M., Sánchez‐Mejías, E., Trujillo‐Estrada, L., Carmona‐Cuenca, I., Caballero, C., Ruano, D., Gutiérrez, A., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.209718 · Cited by 190
Zhao, W.-Q., Santini, F., Breese, R., Ross, D., Zhang, X. D., Stone, D. J., Ferrer, M., Townsend, M., Wolfe, A. L., Seager, M. A., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.057182 · Cited by 188
Jang, H., Zheng, J., & Nussinov, R. (2007) · Biophysical Journal · doi:10.1529/biophysj.107.110148 · Cited by 191
Arendt, T. (2003) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2003.09.007 · Cited by 189
HIV-1 Tat inhibits neprilysin and elevates amyloid β
Rempel, H. C., & Pulliam, L. (2005) · AIDS · doi:10.1097/00002030-200501280-00004 · Cited by 186
Exosomes neutralize synaptic-plasticity-disrupting activity of Aβ assemblies in vivo
An, K., Klyubin, I. V., Kim, Y., Jung, J. H., Mably, A. J., O’Dowd, S., Lynch, T., Kanmert, D., Lemere, C. A., Finan, G. M., et al. (2013) · Molecular Brain · doi:10.1186/1756-6606-6-47 · Cited by 196
Younan, N. D., & Viles, J. H. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00309 · Cited by 172
Understanding the Amyloid Hypothesis in Alzheimer’s Disease
Paroni, G., Bisceglia, P., & Seripa, D. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180802 · Cited by 194
El‐Agnaf, O. M. A., Paleologou, K. E., Greer, B., Abogrein, A. M., King, J. E., Salem, S. A., Fullwood, N. J., Benson, F. E., Hewitt, R., Ford, K. J., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-1346fje · Cited by 187
The Oxidative Stress Metabolite 4-Hydroxynonenal Promotes Alzheimer Protofibril Formation
Siegel, S. J., Bieschke, J., Powers, E. T., & Kelly, J. W. (2007) · Biochemistry · doi:10.1021/bi061853s · Cited by 186
Singh, S. K., Srivastav, S., Yadav, A. K., Srikrishna, S., & Perry, G. L. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/7361613 · Cited by 196
Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease
Kurochkin, I. V., Guarnera, E., & Berezovsky, I. N. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.10.008 · Cited by 185
Jana, A., & Pahan, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404635200 · Cited by 186
Successful therapies for Alzheimer’s disease: why so many in animal models and none in humans?
Franco, R., & Cedazo-Minguez, A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00146 · Cited by 183
Buttini, M., Yu, G.-Q., Shockley, K., Huang, Y., Jones, B., Masliah, E., Mallory, M., Yeo, T., Longo, F. M., & Mucke, L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-24-10539.2002 · Cited by 183
“…evidence is mounting that ADrelated synaptic degeneration and functional neuronal impairments may be caused primarily by nondeposited forms of A (Lambert et al., 1998; Hartley et al., 1999; Holcomb et al., 1999; Hsia et al., 1999; Lue et al., 1999; McLean et al., 1999; Mucke et al., 2000; Raber…”
BackgroundA Sensitive Aβ Oligomer Assay Discriminates Alzheimer's and Aged Control Cerebrospinal Fluid
Savage, M. J., Kalinina, J., Wolfe, A. L., Tugusheva, K., Korn, R., Cash-Mason, T., Maxwell, J. W., Hatcher, N. G., Haugabook, S. J., Wu, G., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1675-13.2014 · Cited by 187
Figueiredo, C. P., Clarke, J. R., Ledo, J. H., Ribeiro, F. C., Costa, C., Melo, H. M., Mota-Sales, A. P., Saraiva, L. M., Klein, W. L., Sebollela, A. S., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.0482-13.2013 · Cited by 186
Self-citationGarzon, D. J., & Fahnestock, M. L. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.5053-06.2007 · Cited by 182
Kim, J., Anwyl, R., Suh, Y., Djamgoz, M. B. A., & Rowan, M. J. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-04-01327.2001 · Cited by 186
Huang, S.-M., Mouri, A., Kokubo, H., Nakajima, R., Suemoto, T., Higuchi, M., Staufenbiel, M., Noda, Y., Yamaguchi, H., Nabeshima, T., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601372200 · Cited by 182
Metadata
- Authors
- Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., Wals, P., Zhang, C., Finch, C. E., Krafft, G. A., & Klein, W. L.
- Affiliations
- Northwestern University (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 1998-05-26
- Volume
- 95
- Issue
- 11
- Pages
- 6448-6453
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC27787
- OpenAlex
- W2165021720
- Cited by
- 3,506
- References
- 68
- Citations by year
- 2026: 61 · 2025: 69 · 2024: 82 · 2023: 81 · 2022: 101 · 2021: 115 · 2020: 137 · 2019: 105 · 2018: 127 · 2017: 138 · 2016: 139 · 2015: 152 · 2014: 171 · 2013: 188 · 2012: 196
- FWCI
- 29.85
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- amyloid-beta 42, neurotoxicity, Alzheimer's disease, Fyn tyrosine kinase, neuroprotection, hippocampal long-term potentiation, synaptic plasticity, signal transduction, organotypic brain cultures
- MeSH terms
- Alzheimer Disease, Animals, Brain, Cell Membrane, Cells, Cultured, Ligands, Neurotoxins, Amyloid beta-Peptides, Cell Death, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
